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Supplementary Methods:  
 
1. Prescreening criteria 
Prescreening criteria excluded everyone with relevant medical and psychological conditions (5α-
reductase deficiency, Klinefelter’s syndrome, brain tumor, cancer, psychiatric 
diagnosis/diagnoses, high blood pressure, liver disease, kidney disease, angina, cancer, hepatitis, 
renal/kidney impairment, history of epileptic seizures and hypersensitivity to soy/alcohol), 
participants using prescription drugs that could have interfered with the study (oxyphenbutazone, 
insulin, corticosteroids, opioids), participants who self-reported consuming illegal drugs or 
excessive alcohol in the previous 24 hours, and non-native English speakers.  
The institutional review boards of Caltech and Claremont Graduate University approved the 
study, all participants gave informed consent and no adverse events occurred.   
  
2. Tests of randomization 
Age, handedness, sexual orientation, relationship and family status, personal income level, and 
treatment expectancy characteristics of the two groups are summarized in Supplementary Table 
1. Five participants did not report their age and were therefore excluded from all analyses that 
include age as control. We conducted two sample t-tests for differences between T and P group 
characteristics to check whether random assignment resulted in balance on all such variables. 
None of these variables showed significant differences between the groups at a level of p = 0.05 
(see Supplementary Table 1). Two participants (one from each group) self-reported taking T 
treatment on a regular basis; all analyses include all of the participants for which the relevant 
data has been collected, and are robust when the latter two are excluded. To reduce the potential 
effect of a female experimenter’s presence on T-related behaviors,1 male researchers conducted 
all experimental sessions. 
  
3. Hormonal assay procedure  (technical details) 
Steroids were measured by LC-MS/MS using an AB Sciex Triple Quad 5500. Internal standards 
were added to 1 ml of saliva and the steroids extracted by C18 column chromatography with 0.1 
M NH4OH wash followed by 10% acetone. Steroids were eluted from the SPE with 10% 
methanol in acetone and dried under nitrogen. The dried samples were subjected to 
derivatization—the process of transforming a compound into a derivative product of similar 
chemical structure—with pyridine-3-sulfonyl chloride for the estrogens (estrone (E1), estradiol 
(E2), and estriol (E3)). 40 µL sodium bicarbonate (50mM, pH 10) and 40 µL pyridine-3-sulfonyl 
chloride (3 mg/mL in acetonitrile) were added to the dried samples and incubated at 60°C for 10 
minutes. After derivatization, the samples were diluted with 80 µL of water and injected for LC-
MS/MS analysis, with analytical separation performed on an Agilent Poroshell 120 EC-C8 
column and ionization by atmospheric pressure chemical ionization (APCI) in the positive 
ionization mode. Supplementary Table 2 lists each analyte along with its validation results for 
the lower limit of quantitation (LLOQ is jargon for the lowest level of detection with coefficients 
of variation (CVs) < 20% over the linear range), linear range, and the inter-assay precision from 
the highest concentration to the LLOQ within the linear range. When salivary hormone levels of 
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participants were below their LLOQ, we assigned values halfway between zero and their 
respective LLOQ (note that the true quantities of the hormone in the sample are never zero, even 
when they do not reach the detection threshold). 
4. Hormonal changes following treatment and manipulation check 
As expected, we found significant post-treatment differences between groups with respect to all 
hormones influenced by T treatment (see Fig. 1, Supplementary Table 3), either as an upstream 
(androstenedione) or downstream (5-alpha DHT) metabolite of T.
2 
Additionally, we found a 
decrease in progesterone 170H resulting from an increase in T. The changes in saliva T measures 
were similar in magnitude to those reported in previous studies following topical gel 
administration of T and progesterone.
3,4
 We observed no significant differences between 
treatment groups in hormones that were not expected to change following short-term T treatment 
(e.g., aldosterone, cortisol, cortisone, melatonin) in all four saliva measurements throughout the 
experiment (i.e., the pre-treatment and the three post-treatment measurements). The pre-
treatment and first post-treatment mean hormonal saliva levels are summarized in Supplementary 
Table 3; note that differences between morning and afternoon hormonal levels (of both groups) 
were affected by diurnal cycles.
5–7
 
From assays conducted during the first 13 (out of 17) sessions of the study, we noted that 72 out 
of 184 pre-treatment baseline saliva samples (in both treatment groups) presented measurements 
with higher T levels than are expected in normal young men (greater than 400 pg/mL). All other 
measurements (including T metabolites) were hormonally typical. We traced the cause of these 
abnormal measurements to T gel transfer to common surfaces (e.g., doorknobs, mouse pads). 
Crucially, the high measurements were caused by local spread of T into saliva tubes, but 
physiological levels were unaffected by superficial contact with the dry nuisance T gel, as (a) we 
observed normal pre-treatment levels of T metabolites, namely DHT and androstenedione, in all 
participants; (b) none of the placebo group participants showed abnormally high values of T 
metabolites in any of the post-treatment measurements; (c) only five out of 118 participants from 
the placebo group showed consistently elevated T measurements in all three of the post-
treatment saliva samples; and (d) previous investigations found that interpersonal T transfer is 
highly unlikely even with skin-to-skin contact.
8
 Thus, we found convergent evidence that 
biofluid levels were unaffected by superficial contact.  
In response to this finding during the course of the experimental period, we identified all surfaces 
and objects through which T could spread in the facility and improved sterile isolation protocol 
to eliminate the spread of the dried T gel. This protocol included thorough cleaning of 
keyboards, computer mice, chair backs, displays, and all doorknobs with a bleach-alcohol 
solution after each session as well as asking participants to carefully wipe hands with a wet tissue 
before collecting each saliva sample. New pens were used for each session, and all previously 
used pens were removed from the testing area. Clipboards and other miscellaneous objects that 
participants did or could interact with were cleaned, and an aerosol air sanitizer that bonds to 
volatile organic compounds (VOCs) was sprayed into the air. Following the adoption of this 
strict sterilization protocol, we found a drastic reduction in incidence of high T samples in the 
pre-treatment measurements, to a total of five participants out of 58 in the following four 
sessions (sessions 14–17). 
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5. Digit ratio measurements 
The ratio of second (index) finger length to fourth (ring) finger (abbreviated 2D:4D) is 
considered a proxy for prenatal T exposure,
9
 although this hypothesis is still under debate.
10,11
 
Participants’ 2D:4D ratios were measured by two independent raters using hand scans and digital 
calipers (correlation between the two raters was ~0.95). The right-hand digit ratio was not 
calculated for one participant due to a broken finger, and therefore he was excluded from all 
analyses that use the right-hand digit ratio as control. Correlation between the digit ratios of the 
left and right hands was 0.64, p = 0.0001. There were slight differences between the two 
treatment groups in the right-hand 2D:4D (T: M = 0.943, SD = 0.033; P: M = 0.953, SD = 0.033; 
t(240) = 2.19, p = 0.03, 95% CI [–0.018 –0.001]) and no differences in the left-hand 2D:4D (T: 
M = 0.945, SD = 0.033; P: M = 0.947, SD = 0.033; t(241) = –0.57, p = 0.56, 95% CI [–0.011 
0.006]). Regression models are reported for the right hand. All of the results hold when replacing 
the right-hand 2D:4D by either the left-hand digit ratio or the averaged digit ratio of both hands. 
6. Mood questionnaire  
To test whether our results could be due to changes in the mood state of our participants, we 
measured mood using the PANAS-X scale,
12
 both pre-treatment (in the morning) and post-
treatment (in the afternoon). Supplementary Table 4 shows a modest decrease in both affect 
measures over time (morning vs. afternoon) and no treatment or time x treatment interaction, 
indicated by the output of two-way analysis of variance (ANOVA) with an interaction term, 
ruling out this indirect way in which T might affect cognition and behavior. Three participants 
did not answer all of the negative affect items, and five participants did not complete all of the 
positive affect items; these participants were excluded from analyses that include these scales as 
control variables. 
7. Extended data analysis and results for task 1 
The influence of T administration on preferences for brands varying in social rank 
association. We estimated a linear regression mixed models with random intercepts for brand 
pair and participant
13
 (using fixed-effect models yielded similar results). The dependent variable 
(DV) in all models was the preference rating (z-scored at the question level), such that higher 
rating implied greater preference for the brand high in social rank. All analyses were conducted 
using the function lmer implemented in R.
14
  
Model A1 included only treatment (T = 1, placebo = 0) as an independent variable (IV). Model 
A2 also included age, positive and negative affect, treatment expectancy, and the right hand 
2D:4D (results hold when the left hand or the average of the two hands is used). Model A3 
included all of the IVs of model A2 with the addition of all of the hormonal levels that were not 
affected by the treatment, as measured from the first post-treatment saliva sample (i.e., the 
second overall sample). We replicated model A3’s results where the measurements were 
replaced by either the second post-treatment saliva sample (i.e., the third overall measurement, 
model A4) or the baseline (morning) saliva sample (model A5). The results are summarized in 
Supplementary Table 7. 
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Testing for a dispositional effect of T on preferences for brands varying in social rank 
association. We repeated the analyses above (testing for the influence of T administration on 
task 1), this time when including either the logged baseline (pre-treatment) T levels, or the 
logged baseline levels of androstenedione. The latter is a downstream metabolite of testosterone, 
which levels correlate with testosterone (in our sample the correlation was 0.44), and that was 
suggested (by animal studies) to have potent behavioral effect that are similar to testosterone.15,16 
 
Model F1, F2, and F3 are identical to models A1, A2, and A3, but also include the logged 
baseline T levels. Models F4, F5, and F6 repeated these analyses, this time with baseline levels 
of androstenedione instead of testosterone. The results are summarized in Supplementary Table 
12. 
8. Extended data analysis and results for task 2 
T’s influence on attitudes toward goods promoting different strategies to enhance social 
rank. Our main hypothesis was that T increased attitudes toward goods described as status-
enhancing, as opposed to power-enhancing or higher in quality. We tested this hypothesis by 
estimating linear regression mixed models
13
 with participant random intercepts and slopes for 
“power” and “status” positioning, and product random intercepts. The DV of all models was the 
goods’ attitude score, such that a high score reflected a more positive attitude toward the good. 
The IVs were a binary treatment indicator (T = 1, placebo = 0), two binary indicators denoting 
description as power-enhancing or status-enhancing (i.e., quality was the baseline), and 
interaction terms between treatment and the two description conditions (i.e., power and status). A 
positive interaction implies that T-treated participants put a greater weight on the corresponding 
attribute compared to the placebo group; the binary treatment effect estimates the weight that the 
T-treated participants put on the baseline “quality” description compared to the placebo group.  
All analyses were conducted using the function lmer implemented in R.
14
 Model B1 included all 
the IVs discussed above; model B2 also included age, positive and negative affect, treatment 
expectancy, and the right hand 2D:4D (results hold when the left hand or the average between 
the two hands is used). Model B3 included all of the IVs of model B2 and all of the hormonal 
levels that were not affected by the treatment, as measured from the first post-treatment saliva 
sample. We replicated model B3’s results when the measurements were replaced by either the 
second post-treatment saliva sample (i.e., the third overall measurement, model B4) or the 
baseline (morning) saliva sample (model B5). The results are summarized in Supplementary 
Table 8. 
We further tested the treatment’s influence for each description condition in isolation, using a 
simple slope analysis estimating model B1 separately for quality (model C1), power (model C2), 
and status (model C3) ads (Supplementary Table 9). 
Finally, we directly tested for differences in attitudes toward power and status ads by applying 
the same analytical strategy to the power and status ads alone (i.e., excluding quality), when 
employing the power category as the baseline (Supplementary Table 11). 
Testing for a dispositional effect of T on attitudes toward goods promoting different 
strategies to enhance social rank. We repeated the analyses above (testing for the influence of 
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T administration on task 2), this time when including either the logged baseline (pre-treatment) T 
levels, or the baseline levels of androstenedione. 
 
Model G1, G2, and G3 are identical to models B1, B2, and B3, but also include the logged 
baseline T levels. Models G4, G5, and G6 repeated these analyses, this time with baseline levels 
of androstenedione instead of testosterone. The results are summarized in Supplementary Table 
13.  
T’s influence on hypothetical purchase behavior for goods promoting different strategies to 
enhance social rank. We applied the same analytic strategy we used for the attitude scores to 
investigate the influence of T on the secondary measure of general purchase intentions. The 
models also included controls for ownership status and general buying intentions for the good 
category (self-reported in the post-experimental survey); both were significant predictors (p < 
0.01) of the DV. The results are summarized in Supplementary Table 10. 
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Supplementary Figure 1. Summary of pretest of text descriptions: Mean quality, power and 
status perception ratings of the text descriptions across the three conditions focusing on (1) 
quality, (2) power, and (3) status. Error bars denote s.e.m.  
 
 
 
Supplementary Figure 2. Preference toward the high (versus low) social rank brands for the 
two treatment groups (z-scored at the pair level). 
 
 8 
Supplementary Figure 3. Attitudes towards goods positioned as either status (Status = 1) or 
non-status (i.e., quality, power, Status=0) by treatment condition (z-scored at the ad level). 
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Supplementary Table 1. Self-reported demographics (standard errors in parentheses) 
 All T Placebo p-values for t-
test of difference 
N 243 118 125  
Age 23.63 
(0.46) 
24.42 
(0.77) 
22.78 
(0.49) 
0.08 
Left-handed 
(proportion) 
0.074 
(0.02) 
0.064 
(0.02) 
0.085 
(0.03) 
0.54 
Heterosexual 
(proportion) 
0.90 
(0.02) 
0.91 
(0.03) 
0.89 
(0.03) 
0.56 
Treatment 
expectancy
1
 
2.76 
(0.06) 
2.67 
(0.08) 
2.85 
(0.09) 
0.16 
Married 
(proportion) 
0.08 
(0.02) 
0.09 
(0.03) 
0.08 
(0.03) 
0.74 
 
In a relationship 
(proportion) 
0.38 
(0.03) 
0.34 
(0.05) 
0.42 
(0.04) 
0.20 
Has children 0.06 
(0.02) 
0.08 
(0.02) 
0.04 
(0.02) 
0.23 
Personal monthly 
income
2
 
2.05 
(0.11) 
2.02 
(0.14) 
2.07 
(0.16) 
0.84 
1
 5-point scale: 1 = definitely did not get T, 2 = probably not, 3 = unsure, 4 = probably got T, 5 = 
definitely got T 
2
 5-point scale: 1 = under $500/month, 2 = $501–$1,000/month, 3 = $1,001–$1,500/month, 4 = 
$1,501–$2,000/month, 5 = over $2001/month 
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Supplementary Table 2. Detection levels, precision, and normality tests of hormonal assay 
Analyte (pg/ml) LLOQ Range Precision Proportion 
undetected, 
sample A 
Intra-
assay 
COV 
Inter-
assay 
COV 
Proportion 
undetected, 
sample B 
K-S test 
p-value 
K-S test 
(log) p-
value 
Estrone 0.5 0.5–510 8.7–13.7% 0.132 7.9% 11.9% 0.257 <0.01 0.56 
Estradiol 0.3 0.3–510 4.3–18.7% 0.128 8.7% 12.2% 0.329 0.06 0.88 
Testosterone  3.0 3.0–5100 3.0–18.1% 0 4.7% 10.3% 0.008 <10-20 <0.01 
Androstenedione  5.0 5.0–2300 5.2–6.6% 0 5.3% 5.3% 0.008 <10-20 0.008 
DHEA 20.0 20.0–1800 4.1–15.2% 0.004 6.7% 10.5% 0.012 0.002 0.98 
DHT 10.0 10.0–920 3.6–17.7% 0.786 6.6% 14.8% 0.473 <10-11 0.02 
Progesterone 10.0 10.0–10000 4.8–10.8% 0.794 5.1% 9.5% 0.753 <0.01 0.03 
17OH-
Progesterone  
5.0 5.0–630 3.9–13.8% 0.004 6.1% 11.1% 0.061 0.003 0.98 
11-Deoxycortisol  5.0 5.0–410 6.8–16.6% 0.132 6.3% 9.2% 0.473 <0.01 0.04 
Cortisol 0.1 0.1–52 5.1–17.9% 0 4.5% 10.7% 0.008 <0.01 0.92 
Cortisone 0.1 0.1–81 4.1–14.9% 0 5.6% 8.2% 0.008 0.07 0.59 
Corticosterone  5.0 5.0–1800 4.6–17.5% 0.313 7.9% 10.0% 0.312 <0.01 0.08 
Aldosterone 10.0 10.0–560 8.9–18.8% 0.272 6.2% 14.9% 0.272 <0.06 0.39 
Melatonin 2.5 2.5–10000 5.2–15.9% 0.502 6.9% 9.1% 0.500 0.07 0.14 
Note: p-values are calculated using a Kolmogorov-Smirnov test for the distributions of the 
second saliva sample compared to Gaussian, and for the log-transform (the null hypothesis is 
normal Gaussian distribution). 
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Supplementary Table 3. Hormonal measurements in log(pg/mL) (standard errors in 
parentheses) 
 Placebo Testosterone 
Two-tailed p-value from t-
test of T–placebo equality 
Sampling time
1
 9 a.m. 2 p.m. 9 a.m. 2 p.m. 9 a.m. 2 p.m. 
Testosterone 5.743 5.111 5.580 8.373 0.267 1.06E-13 
 (0.085) (0.085) (0.084) (0.151)   
Androstenedione 4.510 4.205 4.525 5.462 0.634 3.11E-09 
 (0.039) (0.044) (0.034) (0.084)   
DHT 1.984 1.867 1.905 3.482 0.745 2.38E-06 
 (0.069) (0.051) (0.060) (0.114)   
Progesterone 1.937 2.002 1.829 1.883 0.36 0.41 
 (0.058) (0.064) (0.052) (0.055)   
Progesterone170H 3.245 2.675 3.217 2.463 0.792 0.008 
 (0.050) (0.058) (0.049) (0.058)   
Estrone –0.088 –0.557 –0.007 –0.389 0.29 0.42 
 (0.063) (0.066) (0.064) (0.056)   
Estradiol –0.743 –1.158 –0.766 –1.066 0.86 0.44 
 (0.052) (0.059) (0.054) (0.054)   
DHEA 5.198 4.570 5.116 4.557 0.30 0.76 
 (0.053) (0.058) (0.051) (0.054)   
Deoxycortisol11 2.579 1.650 2.568 1.584 0.66 0.35 
 (0.079) (0.072) (0.083) (0.064)   
Cortisol 1.047 0.062 1.045 0.077 0.68 0.81 
 12 
 (0.058) (0.065) (0.057) (0.058)   
Cortisone 2.539 1.952 2.539 2.003 0.70 0.76 
 (0.030) (0.060) (0.034) (0.050)   
Corticosterone 2.442 1.274 2.646 1.290 0.37 0.76 
 (0.126) (0.065) (0.123) (0.060)   
Aldosterone 2.640 2.516 2.634 2.395 0.82 0.14 
 (0.067) (0.071) (0.068) (0.066)   
Melatonin 1.045 0.276 1.221 0.353 0.27 0.23 
 (0.093) (0.029) (0.101) (0.051)   
1
 Main effects of time (afternoon vs. treatment) are due to the diurnal cycles of the hormones.
 5-7
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Supplementary Table 4. Positive/negative affect (PANAS) summary statistics 
 All Testosterone Placebo ANOVA: p-values 
Time Morning Afternoon Morning Afternoon Morning Afternoon T Time T x time 
 
Positive affect 2.72 
(0.05) 
2.61 
(0.06) 
2.72 
(0.06) 
2.63 
(0.08) 
2.72 
(0.07) 
2.60 
(0.09) 
 
0.85 
 
0.16 0.85 
Negative affect 1.53 
(0.04) 
1.45 
(0.04) 
1.53 
(0.06) 
1.46 
(0.05) 
1.53 
(0.05) 
1.43 
(0.05) 
0.77 
 
0.13 
 
0.84 
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Supplementary Table 5. Manipulation check of brand associations. The table summarizes 
the participants’ quality and social rank (combination of power and status) associations of the 
five pair brands used in the experimental task. The two right columns denote the 95% confidence 
interval of the difference in difference between the brands’ associations with social rank and 
quality. 
Brand H Brand L Rank 
H 
Rank 
L 
Rank 
Diff. 
Quality 
H 
Quality 
L 
Quality 
Diff. 
Diff. in diff.   
95%  CI 
Giorgio 
Armani 
North 
Face 
80.15 46.39 33.76 73.48 77.75 –4.27 [33.33 42.73] 
Ralph Lauren North 
Face 
68.25 46.39 21.86 67.21 77.75 –10.45 [27.89 36.72] 
Ralph Lauren Old Navy 68.25 20.20 47.95 67.21 36.88 30.32 [12.87 22.40] 
Calvin Klein Levi’s  60.61 35.83 24.75 64.09 73.67 –9.58 [29.79 38.88] 
Lacoste Levi’s  57.57 35.83 21.78 58.81 73.67 –15.15 [31.73 42.12] 
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Supplementary Table 6. T’s  influence on brand associations . Mean quality and social rank 
associations of the different brands across the two treatment groups, and 95% confidence interval 
of a two-sample t-test comparing them. 
 Quality Social rank  
 T Placebo 95%  CI 
of Diff 
T Placebo 95%  CI 
of Diff 
Giorgio Armani 60.08 57.43 [–3.690   7.391] 56.30 58.93 [–3.075  6.385] 
Ralph Lauren 68.86 65.47 [–1.935  8.711] 68.00 68.51 [–5.845  4.836] 
Calvin Klein 67.70 60.23 [1.849  13.098]* 60.97 60.24 [–5.090 6.559] 
Lacoste 60.08 57.43 [–3.723  9.025] 56.30 58.93 [–9.188  3.930] 
North Face 75.80 79.81 [–9.158  1.131] 44.77 48.09 [ –8.996  2.342] 
Old Navy 36.56 37.21 [–6.663  5.348] 20.27 20.13 [–4.594  4.861] 
Levi's  73.82 73.52 [–5.050  5.639] 36.47 35.16 [–4.180  6.799] 
Note: *p < 0.01 
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Supplementary Table 7: T’s influence on preference for brands high in social rank (task 1), 
estimated using mixed model linear regressions with participant and brand random intercepts. 
Hormonal measurements are logged; standard errors in parentheses. 
 
 Dependent variable:  
Brand preference rating (z-scored) 
 (A1) (A2) (A3) (A4) (A5) 
Treatment 0.182
**
 0.215
**
 0.190
*
 0.173
*
 0.232
**
 
 (0.091) (0.096) (0.100) (0.100) (0.097) 
Age  –0.015** –0.012* –0.017** –0.010 
  (0.007) (0.007) (0.007) (0.007) 
Negative affect  –0.060 –0.062 –0.100 –0.099 
  (0.089) (0.094) (0.092) (0.090) 
Positive affect  0.017 0.027 0.024 0.030 
  (0.050) (0.052) (0.052) (0.051) 
Belief  0.076 0.092
*
 0.087
*
 0.097
*
 
  (0.051) (0.052) (0.052) (0.051) 
Digit ratio (right)  1.137 0.903 1.459 1.463 
  (1.368) (1.402) (1.407) (1.368) 
Estrone   0.026 0.067 –0.172** 
   (0.078) (0.074) (0.081) 
Estradiol   –0.010 0.048 0.138 
   (0.082) (0.083) (0.092) 
DHEA   0.049 0.069 0.105 
   (0.103) (0.089) (0.100) 
Progesterone   –0.001 –0.139 –0.130 
   (0.074) (0.086) (0.082) 
Deoxycortisol11   0.037 –0.030 0.096 
   (0.091) (0.085) (0.086) 
Cortisol   –0.205 0.012 –0.180 
   (0.156) (0.113) (0.159) 
Cortisone   0.352
*
 0.165 0.153 
   (0.205) (0.122) (0.257) 
Corticosterone   0.043 –0.144 –0.066 
   (0.082) (0.099) (0.057) 
Aldosterone   0.049 0.111 0.158
**
 
   (0.066) (0.101) (0.068) 
Melatonin   0.019 0.088 0.048 
   (0.106) (0.112) (0.052) 
Constant –0.094 –1.020 –2.066 –1.562 –2.426 
 (0.065) (1.317) (1.476) (1.477) (1.504) 
Observations 1,215 1,145 1,135 1,145 1,145 
Log likelihood –1,603.223 –1,513.236 –1,511.742 –1,522.513 –1,521.555 
Akaike inf. crit. 3,216.446 3,046.472 3,063.485 3,085.025 3,083.110 
Bayesian inf. crit. 3,241.959 3,096.903 3,164.172 3,185.888 3,183.973 
 
Note: 
*p < 0.1 **p < 0.05 ***p < 0.01 
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Supplementary Table 8. Treatment influence on attitudes toward goods (task 2), estimated 
using mixed model linear regressions with participant random intercepts and slopes for “power” 
and “status” positioning, and product random intercepts. Hormonal measurements are logged; 
standard errors in parentheses. 
 
Dependent variable:  
 
Attitude score (z-scored) 
 
(B1) (B2) (B3) (B4) (B5) 
Treatment -0.044 -0.086 -0.044 -0.044 -0.048 
 
(0.102) (0.104) (0.105) (0.105) (0.106) 
Power 0.007 0.011 0.029 0.029 0.011 
 
(0.082) (0.085) (0.084) (0.084) (0.085) 
Treatment x Power -0.017 -0.027 -0.031 -0.031 -0.027 
 (0.115) (0.119) (0.118) (0.118) (0.119) 
Status -0.143
*
 -0.152
*
 -0.133 -0.133 -0.152
*
 
 
(0.085) (0.086) (0.086) (0.086) (0.086) 
Treatment x Status 0.275
**
 0.249
**
 0.237
**
 0.237
**
 0.249
**
 
 (0.119) (0.120) (0.120) (0.120) (0.120) 
Age 
 
0.011
**
 0.014
**
 0.014
**
 0.012
**
 
  
(0.005) (0.006) (0.006) (0.006) 
Negative affect 
 
0.112 0.136
*
 0.136
*
 0.099 
  
(0.070) (0.074) (0.074) (0.073) 
Positive affect 
 
0.113
***
 0.103
**
 0.103
**
 0.114
***
 
  
(0.040) (0.041) (0.041) (0.041) 
Belief 
 
-0.050 -0.043 -0.043 -0.045 
  
(0.041) (0.041) (0.041) (0.042) 
Digit ratio (right) 
 
-0.855 -1.022 -1.022 -0.736 
  
(1.085) (1.107) (1.107) (1.121) 
Estrone 
  
-0.055 -0.055 -0.101
*
 
   
(0.061) (0.061) (0.059) 
Estradiol 
  
-0.139
**
 -0.139
**
 -0.057 
   
(0.065) (0.065) (0.066) 
DHEA 
  
0.037 0.037 -0.006 
   
(0.081) (0.081) (0.071) 
Progesterone 
  
0.052 0.052 -0.077 
   
(0.059) (0.059) (0.068) 
Deoxycortisol11 
  
-0.010 -0.010 0.027 
   
(0.072) (0.072) (0.068) 
Cortisol 
  
-0.164 -0.164 -0.008 
   
(0.123) (0.123) (0.090) 
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Cortisone 
  
0.057 0.057 -0.072 
   
(0.162) (0.162) (0.097) 
Corticosterone 
  
0.061 0.061 -0.038 
   
(0.065) (0.065) (0.079) 
Aldosterone 
  
0.053 0.053 0.078 
   
(0.052) (0.052) (0.080) 
Melatonin 
  
0.017 0.017 0.010 
   
(0.083) (0.083) (0.089) 
Constant 0.024 0.314 -0.405 -0.405 0.200 
 
(0.073) (1.046) (1.166) (1.166) (1.177) 
Observations 1,446 1,362 1,350 1,350 1,362 
Log Likelihood -1,995.502 -1,867.973 -1,860.620 -1,860.620 -1,880.624 
Akaike Inf. Crit. 4,019.004 3,773.945 3,779.241 3,779.241 3,819.248 
Bayesian Inf. Crit. 4,092.875 3,873.063 3,930.269 3,930.269 3,970.533 
Note: 
*
p < 0.1 
**
p < 0.05 
***
p < 0.01 
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Supplementary Table 9. Treatment influence on attitude toward the goods, by positioning 
condition). Each column shows the results of a linear regression analysis using a mixed model 
with participant and product random intercepts. 
 Dependent variable: 
 Attitude score (z-scored) 
 (C1) 
Quality 
(C2) 
Power 
(C3) 
Status 
Treatment –0.046 –0.063 0.231** 
 (0.102) (0.102) (0.099) 
Constant 0.025 0.031 –0.119* 
 (0.073) (0.073) (0.071) 
Observations 482 481 483 
Log likelihood –676.661 –673.603 –677.509 
Akaike inf. crit. 1,363.322 1,357.205 1,365.018 
Bayesian inf. crit. 1,384.211 1,378.085 1,385.918 
 
Note: 
*
p < 0.1 
**
p < 0.05 
***
p < 0.01 
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Supplementary Table 10. Treatment influence on hypothetical purchase behavior for goods 
(task 2), estimated using mixed model linear regressions with participant random intercepts and 
slopes for “power” and “status” positioning, and product random intercepts. Hormonal 
measurements are logged, standard errors in parentheses. 
 
Dependent variable:  
 
General purchase intentions  
 
(D1) (D2) (D3) (D4) (D5) 
Treatment -0.042 -0.070 -0.063 -0.048 -0.076 
 
(0.084) (0.085) (0.088) (0.089) (0.087) 
Power 0.044 0.065 0.070 0.065 0.066 
 
(0.072) (0.073) (0.073) (0.073) (0.073) 
Treatment x Power 0.020 0.011 0.014 0.010 0.010 
 (0.099) (0.101) (0.102) (0.101) (0.102) 
Status -0.109 -0.090 -0.079 -0.089 -0.089 
 
(0.067) (0.069) (0.069) (0.069) (0.069) 
Treatment x Status 0.160
*
 0.138 0.135 0.138 0.138 
 (0.093) (0.096) (0.096) (0.096) (0.096) 
Buy 0.057
***
 0.058
***
 0.057
***
 0.058
***
 0.057
***
 
 
(0.010) (0.011) (0.011) (0.011) (0.011) 
Own 0.139
***
 0.146
***
 0.136
***
 0.148
***
 0.149
***
 
 
(0.049) (0.051) (0.051) (0.051) (0.051) 
Age 
 
0.008
*
 0.009
*
 0.010
*
 0.008 
  
(0.005) (0.005) (0.005) (0.005) 
Negative affect 
 
0.073 0.089 0.068 0.084 
  
(0.063) (0.067) (0.066) (0.065) 
Positive affect 
 
0.103
***
 0.099
**
 0.114
***
 0.110
***
 
  
(0.037) (0.038) (0.039) (0.038) 
Belief 
 
-0.072
*
 -0.074
*
 -0.067
*
 -0.071
*
 
  
(0.037) (0.038) (0.038) (0.038) 
Digit Ratio (right) 
 
-0.687 -0.818 -0.556 -0.644 
  
(0.981) (1.014) (1.019) (0.996) 
Estrone 
  
0.009 -0.035 0.010 
   
(0.055) (0.053) (0.058) 
Estradiol 
  
-0.009 -0.016 0.012 
   
(0.058) (0.059) (0.065) 
DHEA 
  
0.065 0.070 0.096 
   
(0.073) (0.064) (0.072) 
Progesterone 
  
0.012 -0.046 -0.053 
   
(0.053) (0.061) (0.060) 
Deoxycortisol11 
  
0.061 0.038 0.078 
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(0.065) (0.061) (0.062) 
Cortisol 
  
-0.246
**
 -0.126 -0.159 
   
(0.111) (0.081) (0.114) 
Cortisone 
  
0.123 -0.053 -0.164 
   
(0.146) (0.087) (0.184) 
Corticosterone 
  
0.070 0.033 0.039 
   
(0.059) (0.071) (0.041) 
Aldosterone 
  
0.009 0.047 0.018 
   
(0.048) (0.072) (0.049) 
Melatonin 
  
-0.035 0.030 -0.030 
   
(0.075) (0.079) (0.037) 
    
-0.035 0.010 
Constant -0.211
***
 0.076 -0.569 -0.510 -0.109 
 
(0.076) (0.945) (1.064) (1.065) (1.087) 
Observations 1,401 1,330 1,318 1,330 1,330 
Log Likelihood -1,678.013 -1,595.558 -1,591.104 -1,610.562 
-
1,609.879 
Akaike Inf. Crit. 3,388.026 3,233.117 3,244.208 3,283.123 3,281.757 
Bayesian Inf. Crit. 3,471.945 3,342.169 3,404.908 3,444.104 3,442.738 
Note: 
*
p < 0.1 
**
p < 0.05 
***
p < 0.01 
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Supplementary Table 11. Treatment influence on attitudes toward goods (task 2), mixed 
model linear regression with participant random intercepts and slopes for “power” and 
“status” positioning, and product random intercepts. The data includes only the “power” and 
“status” conditions, with “power” as the baseline. Hormonal measurements are logged; standard 
errors in parentheses. 
 
Dependent variable:  
Attitude score (z-scored) 
 
(E1) (E2) (E3) (E4) (E5) 
Treatment -0.061 -0.112 -0.061 -0.085 -0.091 
 
(0.102) (0.105) (0.106) (0.108) (0.106) 
Status -0.150
*
 -0.164
*
 -0.162
*
 -0.164
*
 -0.164
*
 
 
(0.086) (0.088) (0.088) (0.088) (0.088) 
Treatment x Status 0.293
**
 0.278
**
 0.270
**
 0.278
**
 0.278
**
 
 (0.121) (0.122) (0.123) (0.122) (0.122) 
Age 
 
0.010
*
 0.014
**
 0.012
*
 0.011
*
 
  
(0.006) (0.006) (0.006) (0.006) 
Negative affect 
 
0.141
*
 0.151
*
 0.130 0.153
*
 
  
(0.077) (0.081) (0.080) (0.080) 
Positive affect 
 
0.114
***
 0.099
**
 0.114
**
 0.102
**
 
  
(0.044) (0.045) (0.045) (0.045) 
Belief 
 
-0.066 -0.054 -0.061 -0.065 
  
(0.044) (0.045) (0.046) (0.045) 
Digit Ratio (right) 
 
-0.403 -0.674 -0.297 -0.191 
  
(1.185) (1.204) (1.230) (1.205) 
Estrone 
  
-0.055 -0.094 -0.060 
   
(0.067) (0.065) (0.071) 
Estradiol 
  
-0.159
**
 -0.083 -0.089 
   
(0.070) (0.073) (0.081) 
DHEA 
  
0.073 0.024 0.109 
   
(0.088) (0.078) (0.088) 
Progesterone 
  
0.100 -0.066 -0.029 
   
(0.064) (0.075) (0.073) 
Deoxycortisol11 
  
-0.001 -0.031 0.078 
   
(0.079) (0.075) (0.076) 
Cortisol 
  
-0.125 0.027 0.071 
   
(0.134) (0.099) (0.140) 
Cortisone 
  
0.024 -0.018 -0.180 
   
(0.176) (0.107) (0.229) 
Corticosterone 
  
0.028 -0.051 -0.035 
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(0.071) (0.087) (0.050) 
Aldosterone 
  
0.082 0.110 -0.034 
   
(0.057) (0.088) (0.060) 
Melatonin 
  
0.014 -0.006 -0.028 
   
(0.091) (0.098) (0.045) 
Constant 0.031 -0.084 -0.955 -0.414 -0.513 
 
(0.073) (1.142) (1.270) (1.292) (1.327) 
Observations 964 908 900 908 908 
Log Likelihood -1,341.313 -1,257.150 -1,256.238 -1,269.867 -1,270.497 
Akaike Inf. Crit. 2,700.627 2,542.300 2,560.477 2,587.734 2,588.995 
Bayesian Inf. Crit. 2,744.467 2,609.657 2,675.734 2,703.203 2,704.464 
Note: 
*
p < 0.1 
**
p < 0.05 
***
p < 0.01 
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Supplementary Table 12: The influence of baseline testosterone and androstenedione levels 
on preference for brands high in social rank (task 1), mixed model linear regression with 
participant and brand random intercepts. Hormonal measurements are logged; standard 
errors in parentheses. 
 
 
Dependent variable: 
 
Brand preference rating (z-scored) 
 
(F1) (F2) (F3) (F4) (F5) (F6) 
Testosterone (baseline) 0.130
***
 0.127
**
 0.138
***
 
   
 
(0.046) (0.050) (0.052) 
   
Androstenedione (baseline) 
   
0.301
***
 0.251
**
 0.205 
    
(0.111) (0.119) (0.131) 
Treatment 0.206
**
 0.223
**
 0.197
**
 0.182
**
 0.207
**
 0.185
*
 
 
(0.090) (0.095) (0.098) (0.089) (0.095) (0.099) 
Age 
 
–0.012* –0.010 
 
–0.011* –0.010 
  
(0.006) (0.007) 
 
(0.007) (0.007) 
Negative affect  
 
–0.061 –0.070 
 
–0.055 –0.058 
  
(0.088) (0.092) 
 
(0.088) (0.093) 
Positive affect  
 
0.033 0.047 
 
0.028 0.036 
  
(0.050) (0.052) 
 
(0.050) (0.052) 
Belief 
 
0.073 0.090
*
 
 
0.074 0.087
*
 
  
(0.051) (0.052) 
 
(0.051) (0.052) 
Digit ratio (right) 
 
0.808 0.658 
 
1.091 0.912 
  
(1.358) (1.385) 
 
(1.358) (1.397) 
Estrone 
  
0.025 
  
0.026 
   
(0.076) 
  
(0.077) 
Estradiol 
  
0.020 
  
–0.009 
   
(0.081) 
  
(0.082) 
DHEA 
  
0.040 
  
0.016 
   
(0.101) 
  
(0.104) 
Progesterone 
  
–0.014 
  
–0.005 
   
(0.073) 
  
(0.074) 
Deoxycortisol11 
  
0.029 
  
0.029 
   
(0.090) 
  
(0.091) 
Cortisol 
  
–0.205 
  
–0.168 
   
(0.154) 
  
(0.157) 
Cortisone 
  
0.360
*
 
  
0.283 
   
(0.202) 
  
(0.209) 
Corticosterone 
  
0.019 
  
0.045 
   
(0.082) 
  
(0.082) 
Aldosterone 
  
0.050 
  
0.034 
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(0.065) 
  
(0.067) 
Melatonin 
  
0.026 
  
0.011 
   
(0.104) 
  
(0.105) 
Constant –0.846*** –1.512 –2.563* –1.456*** –2.217 –2.719* 
 
(0.270) (1.315) (1.466) (0.507) (1.425) (1.529) 
Observations 1,215 1,145 1,135 1,215 1,145 1,135 
Log likelihood –1,601.338 –1,512.110 –1,510.239 –1,600.875 –1,512.243 –1,511.638 
Akaike inf. crit. 3,214.676 3,046.220 3,062.477 3,213.749 3,046.486 3,065.276 
Bayesian inf. crit. 3,245.291 3,101.695 3,168.199 3,244.364 3,101.961 3,170.998 
Note: 
*
p < 0.1 
**
p < 0.05 
***
p < 0.01 
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Supplementary Table 13. The influence of baseline testosterone and androstenedione 
levels on attitudes toward goods (task 2), mixed model linear regression with participant 
random intercepts and slopes for “power” and “status” positioning,  and product random 
intercepts. Hormonal measurements are logged; standard errors in parentheses. 
  
 
Dependent variable:  
Attitude score (z-scored) 
 
(G1) (G2) (G3) (G4) (G5) (G6) 
Testosterone (baseline) -0.029 -0.010 -0.025 
   
 
(0.052) (0.055) (0.056) 
   
Testosterone × Power 0.045 0.042 0.062    
 (0.059) (0.063) (0.063)    
Testosterone × Status 0.039 0.050 0.062    
 (0.061) (0.064) (0.064)    
Androstenedione (baseline) 
   
-0.020 0.046 0.041 
    
(0.129) (0.132) (0.138) 
Androstenedione × Power    0.018 0.081 0.122 
    (0.147) (0.150) (0.149) 
Androstenedione × Status    -0.063 -0.023 0.009 
    (0.152) (0.153) (0.152) 
Treatment -0.049 -0.088 -0.048 -0.043 -0.088 -0.045 
 (0.102) (0.104) (0.105) (0.102) (0.104) (0.105) 
Treatment × Power -0.009 -0.023 -0.023 -0.017 -0.029 -0.033 
 (0.116) (0.119) (0.118) (0.115) (0.119) (0.118) 
Treatment × Status 0.282
**
 0.255
**
 0.245
**
 0.276
**
 0.250
**
 0.237
**
 
 (0.120) (0.121) (0.120) (0.119) (0.121) (0.120) 
Power -0.254 -0.231 -0.327 -0.073 -0.354 -0.521 
 
(0.350) (0.371) (0.369) (0.668) (0.685) (0.679) 
Status -0.367 -0.439 -0.490 0.140 -0.050 -0.174 
 
(0.362) (0.375) (0.375) (0.691) (0.695) (0.691) 
Age 
 
0.011
**
 0.014
**
 
 
0.011
**
 0.014
**
 
  
(0.005) (0.006) 
 
(0.005) (0.006) 
Negative affect 
 
0.113 0.135
*
 
 
0.114 0.138
*
 
  
(0.070) (0.074) 
 
(0.070) (0.074) 
Positive affect 
 
0.116
***
 0.106
**
 
 
0.116
***
 0.108
***
 
  
(0.040) (0.041) 
 
(0.040) (0.041) 
Belief 
 
-0.051 -0.043 
 
-0.050 -0.044 
  
(0.041) (0.041) 
 
(0.041) (0.041) 
Digit Ratio (right) 
 
-0.912 -1.054 
 
-0.873 -1.030 
  
(1.092) (1.112) 
 
(1.086) (1.108) 
Estrone 
  
-0.055 
  
-0.056 
   
(0.061) 
  
(0.061) 
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Estradiol 
  
-0.135
**
 
  
-0.139
**
 
   
(0.065) 
  
(0.065) 
DHEA 
  
0.036 
  
0.024 
   
(0.081) 
  
(0.083) 
Progesterone 
  
0.051 
  
0.051 
   
(0.059) 
  
(0.059) 
Deoxycortisol11 
  
-0.011 
  
-0.014 
   
(0.072) 
  
(0.073) 
Cortisol 
  
-0.163 
  
-0.148 
   
(0.123) 
  
(0.125) 
Cortisone 
  
0.058 
  
0.030 
   
(0.162) 
  
(0.166) 
Corticosterone 
  
0.057 
  
0.060 
   
(0.066) 
  
(0.065) 
Aldosterone 
  
0.053 
  
0.046 
   
(0.053) 
  
(0.053) 
Melatonin 
  
0.018 
  
0.014 
   
(0.084) 
  
(0.083) 
Constant 0.193 0.412 -0.223 0.117 0.099 -0.469 
 
(0.309) (1.080) (1.197) (0.590) (1.211) (1.278) 
Observations 1,446 1,362 1,350 1,446 1,362 1,350 
Log Likelihood -2,001.427 -1,873.562 -1,865.931 -1,998.807 -1,870.991 -1,863.298 
Akaike Inf. Crit. 4,040.854 3,791.124 3,795.863 4,035.613 3,785.982 3,790.596 
Bayesian Inf. Crit. 4,141.109 3,905.891 3,962.514 4,135.868 3,900.749 3,957.248 
Note: 
*
p < 0.1 
**
p < 0.05 
***
p < 0.01 
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